Study Evaluating Desvenlafaxine Sustained-Release (DVS-SR) in Adult Outpatients With Major Depressive Disorder

Wyeth

Status and phase: Completed; Phase 3

Conditions: Major Depressive Disorder

Treatments: Drug: DVS-SR 50 mg; Drug: DVS-SR 100 mg; Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT00277823

3151A1-332

Details and patient eligibility

About

The purpose of this study is to compare the antidepressant efficacy, safety, and tolerability of DVS-SR in subjects receiving daily doses of 50 mg or 100 mg of DVS-SR versus subjects receiving placebo.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Clinical diagnosis of major depressive disorder
• Must be able to swallow tablets
• Must be at least 18 years of age.

Exclusion criteria

• Clinical diagnosis of other psychiatric disorders
• Significant risk of suicide
• Unstable medical conditions.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind